Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 24 December 2019, 16:22 HKT/SGT
Share:
    

Source: Eisai
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval
- Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohn's Disease and Psoriatic Arthritis -

TOKYO, Dec 24, 2019 - (JCN Newswire) - Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) announced today that Gilead Sciences K.K. (Tokyo, Japan) and Eisai have entered into an agreement for the distribution and co-promotion of filgotinib, an investigational, oral, selective JAK1 inhibitor, in Japan, pending regulatory approval for the treatment of rheumatoid arthritis (RA). Through this collaboration, Gilead Japan will retain responsibility for manufacturing and marketing approval of filgotinib, while Eisai will be responsible for product distribution in Japan in RA and other potential future indications. The companies will jointly commercialize the medicine if approved.

Approximately 600,000 to 1 million people are living with RA across Japan(1), and despite available options, many still do not experience disease remission. In the global Phase 3 FINCH studies, filgotinib demonstrated durable efficacy and safety results across multiple RA patient populations, including in people with prior inadequate response to methotrexate treatment (MTX), those who were intolerant to one or more biologic treatments and those who were MTX treatment-naive.

"We are very pleased to announce this important new partnership with Eisai, which brings together our complementary expertise and commitment in inflammation, to deliver this important new option to patients living with inflammatory diseases in Japan," said Luc Hermans, M.D., President and Representative Director, Gilead Japan.

"We have extensive clinical development and commercialization experience spanning more than 20 years in RA and have established a solid RA franchise in Japan," said Hidenori Yabune, President of Eisai Japan, Senior Vice President of Eisai. "With this agreement, we look forward to contributing more to patients living with RA by adding filgotinib to our product line-up."

Global studies investigating filgotinib in additional diseases are also underway, including the Phase 3 SELECTION trial in ulcerative colitis, the DIVERSITY Phase 3 trial in Crohn's disease, the Phase 3 PENGUIN trials in psoriatic arthritis, as well as Phase 2 studies in uveitis and in small bowel and fistulizing Crohn's disease.

Gilead and Galapagos NV (Mechelen, Belgium) have entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. Filgotinib is an investigational drug whose efficacy and safety have not been established. Filgotinib is pending regulatory approval in Japan, Europe and the United States based on global Phase 3 trials evaluating its efficacy and tolerability.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company's website at www.gilead.com.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com/.

(1) "Status of RA from the Point of View of Internal Medicine," Study Committee on RA, Working Group on Disease Control, Health Sciences Council, Ministry of Health, Labour and Welfare, March 26, 2018


Dec 24, 2019 16:22 HKT/SGT
Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 9, 2020 11:20 HKT/SGT
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease
July 9, 2020 11:11 HKT/SGT
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
July 8, 2020 13:33 HKT/SGT
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong
July 8, 2020 13:16 HKT/SGT
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma
July 6, 2020 08:33 HKT/SGT
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan
July 6, 2020 08:05 HKT/SGT
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan
July 1, 2020 13:02 HKT/SGT
Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID
June 25, 2020 10:47 HKT/SGT
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea
June 10, 2020 12:49 HKT/SGT
Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa
June 4, 2020 10:43 HKT/SGT
Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: